weight regain and cardiometabolic effects after withdrawal of semaglutide Healthy loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis a randomised placebo-controlled trial Weight regain and cardiometabolic effects

The Wegovy weight loss pen is suitable for individuals who want medically supervised weight reduction and meet the following criteria: Individuals with obesity (BMI 30) who need to reduce or manage weight for health reasons Individuals who are overweight (BMI 27) with weight-related conditions such as diabetes, hypertension, or heart disease Individuals who have attempted diet control and exercise but still struggle to reach their target weight Individuals with irregular eating behaviors, such as frequent snacking or overeating Individuals currently on a weight-loss journey and seeking an additional medical tool to enhance results Who Should Avoid the Wegovy Weight Loss Pen

Originally developed to treat type 2 diabetes, these agonists have been clinically proven to promote significant weight loss by mimicking the effects of the GLP-1 hormone, which plays a crucial role in regulating appetite and blood sugar levels

These medicines help the body release insulin, slow digestion, lower appetite, and manage blood sugar

Tracking progress and evaluating results are essential components of this journey, providing insights into individual successes, challenges, and areas for improvement

A 2025 systematic review mapped weight change after stopping anti-obesity medicines across 11 RCTs